Personalis Reports Preliminary Fourth Quarter and Full Year 2024 Revenue

PSNL 01.07.2025

SERA-AI Powered Highlights
Full Press ReleaseSEC FilingsOur PSNL Tweets

About Gravity Analytica

Recent News

  • 01.13.2025 - New Nature Medicine Publication Shows ctDNA Levels Linked to Recurrence Risk in Lung Cancer
  • 01.07.2025 - Personalis Reports Preliminary Fourth Quarter and Full Year 2024 Revenue
  • 12.19.2024 - Personalis Advances Business Strategy with Investment from Merck and Extends Collaboration with Moderna

Recent Filings

  • 01.10.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
  • 01.07.2025 - EX-99.1 EX-99.1
  • 01.07.2025 - 8-K Current report

Full year revenue of~$84.6 millionrepresents a 15% year-over-year increase

Cash balance of~$185.0 millionexpected to provide runway to cash flow break-even

FREMONT, Calif.--(BUSINESS WIRE)--Jan. 7, 2025--(Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported unaudited preliminary revenue for the fourth quarter and full year endedDecember 31, 2024and preliminary cash balance.

Preliminary Full Year 2024 Revenue

  • Revenue of approximately$84.6 millionfor the full year of 2024 compared with$73.5 millionfor the full year of 2023, an increase of 15%, and above the company’s previous full year guidance range of$83.0to$84.0 million
  • Revenue from pharma tests and services, enterprise sales, and other customers of approximately$77.2 millionfor the full year of 2024 compared with$64.1 millionfor the full year of 2023, an increase of 20%, despite revenue from Natera decreasing 20% to approximately$25.4 millionfor the full year of 2024
  • Revenue from population sequencing for theU.S. Department of Veterans Affairs Million Veterans Program(VA MVP) of approximately$7.4 millionfor the full year of 2024, compared with$9.4 millionfor the full year of 2023, a decrease of 21%

Preliminary Fourth Quarter Revenue, Cash Balance, and Clinical Volume

  • Revenue of approximately$16.8 millionfor the fourth quarter of 2024 compared with$19.7 millionfor the fourth quarter of 2023, a decrease of 15%, primarily due to the expected decline in revenue from Natera and the VA MVP
  • Revenue from pharma tests and services, enterprise sales, and other customers of approximately$16.6 millionfor the fourth quarter of 2024 compared with$18.7 millionfor the fourth quarter of 2023, a decrease of 11%, which includes the expected decrease in revenue from Natera of 41% to approximately$4.2 millionfor the fourth quarter of 2024
  • Cash, cash equivalents, and short-term investments of approximately$185.0 millionas ofDecember 31, 2024; includes the$50 millionstrategic investment from Merck
  • Delivered 1,441 total molecular tests in the fourth quarter of 2024, an increase of 52% compared with 945 tests delivered in the third quarter of 2024

“In 2024, we grew annual revenue approximately 15% and executed on our key priorities and milestones, setting us up well for 2025,” saidChris Hall, Chief Executive Officer and President. “We ended the year strongly with the execution of a long-term commercial collaboration with Moderna and a strategic investment of$50 millionfrom Merck, endorsing our technology platform and capabilities to support our partners’ initiatives, and providing a pathway to cashflow break-even.”

The above information is preliminary and subject to Personalis’ normal quarter and year-end accounting procedures and external audit by the company's independent registered public accounting firm. In addition, these preliminary unaudited results are not a comprehensive statement of the company’s financial results for the year endedDecember 31, 2024, should not be viewed as a substitute for full, audited financial statements prepared in accordance with generally accepted accounting principles, and are not necessarily indicative of the company’s results for any future period.

AboutPersonalis, Inc.

AtPersonalis, we are transforming the active management of cancer through breakthrough personalized testing. We aim to drive a new paradigm for cancer management, guiding care from biopsy through the life of the patient. Our highly sensitive assays combine tumor-and-normal profiling with proprietary algorithms to deliver advanced insights even as cancer evolves over time. Our products are designed to detect minimal residual disease (MRD) and recurrence at the earliest timepoints, enable the selection of targeted therapies based on ultra-comprehensive genomic profiling, and enhance biomarker strategy for drug development.Personalisis based inFremont, California. To learn more, visitwww.personalis.comand connect with us onLinkedInand X (Twitter).

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that are not historical facts and can generally be identified by terms such as “anticipate,” “estimate,” “expect,” “if,” “may,” “future,” “will” or similar expressions. These statements include statements relating to: Personalis’ fourth quarter and full year 2024 preliminary revenue and cash position as ofDecember 31, 2024, increased revenue enabling achievement of Personalis’ current or future priorities, milestones and prospects, and the potential forPersonalisto achieve cashflow break-even in the future. Such forward-looking statements involve known and unknown risks and uncertainties and other factors that may cause actual results to differ materially from any anticipated results or expectations expressed or implied by such statements, including the risks, uncertainties and other factors that relate to the timing and pace of new orders from customers, including from Moderna, Merck, and VA MVP; the success of Personalis’ clinical sales team’s and Tempus AI, Inc.’s sales and marketing efforts; the timing of tissue, blood, and other specimen sample receipts from customers, which can materially impact revenue quarter-over-quarter and year-over-year; Personalis’ ability to demonstrate attributes, advantages or clinical validity of the NeXT platform; the rate of adoption and use of the NeXT platform; the expected benefits of Personalis’ extended collaboration with Moderna; Personalis’ ability to obtain Medicare coverage and reimbursement; andPersonalismay opportunistically raise additional capital through equity offerings, debt financings, collaborations, or licensing arrangements. These and other potential risks and uncertainties that could cause actual results to differ materially from the results predicted in these forward-looking statements are described under the captions “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in Personalis’ Annual Report on Form 10-K for the year endedDecember 31, 2023, filed with theSecurities and Exchange Commission(SEC) onFebruary 28, 2024, as updated by Personalis’ Quarterly Report on Form 10-Q for the quarter endedMarch 31, 2024, filed with theSEConMay 8, 2024, Quarterly Report on Form 10-Q for the quarter endedJune 30, 2024, filed with theSEConAugust 7, 2024, and Quarterly Report on Form 10-Q for the quarter endedSeptember 30, 2024, filed with theSEConNovember 6, 2024. All information provided in this release is as of the date of this press release, and any forward-looking statements contained herein are based on assumptions that we believe to be reasonable as of this date. Undue reliance should not be placed on the forward-looking statements in this press release, which are based on information available to us on the date hereof.Personalisundertakes no duty to update this information unless required by law.

View source version onbusinesswire.com:https://www.businesswire.com/news/home/20250107686915/en/

Investor Relations Contact:Caroline Cornerinvestors@personalis.com646-277-1279

Media:pr@personalis.com

Source:Personalis, Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com